The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN.
The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease.
The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.

开始日期2024-07-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

CTR20241368 / Recruiting临床3期

一项评价Tafasitamab和来那度胺联合吉西他滨和奥沙利铂对比利妥昔单抗联合吉西他滨和奥沙利铂治疗复发/难治性弥漫性大B细胞淋巴瘤患者的有效性和安全性的随机、多中心、III期临床研究

评价Tafasitamab和来那度胺联合GemOx治疗复发/难治弥漫大B淋巴瘤患者的安全耐受性，以及与R-GemOx对比在复发/难治弥漫大B淋巴瘤患者中的有效性及安全性

开始日期2024-05-07

申办/合作机构

北京诺诚健华医药科技有限公司

[+3]

NCT06521255 / Recruiting临床3期

A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom

开始日期2024-05-07

申办/合作机构

北京诺诚健华医药科技有限公司

100 项与坦昔妥单抗相关的临床结果

登录后查看更多信息

100 项与坦昔妥单抗相关的转化医学

登录后查看更多信息

100 项与坦昔妥单抗相关的专利（医药）

登录后查看更多信息

102

项与坦昔妥单抗相关的文献（医药）

2024-12-31·Human vaccines & immunotherapeutics

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Article

作者: Stathis, Anastasios ; Zucca, Emanuele ; Pirosa, Maria Cristina

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (FcγR) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis). In this product review, we will discuss its mechanism of action, safety profile and efficacy results from clinical trials that led to its approval in combination with lenalidomide for patients with R/R DLBCL ineligible for high-dose chemotherapy and autologous transplantation.

2024-11-01·Clinical Lymphoma Myeloma & Leukemia

SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review

Review

作者: Iyengar, Varun ; Hamlin, Paul ; Torka, Pallawi

Older adults (OA) with DLBCL are a heterogenous population with suboptimal outcomes. In this review, we identify and address the unique challenges encountered in the care of OA with DLBCL. We elaborate on the role and limitations of current geriatric assessment (GA) tools and ways to incorporate fitness in therapeutic decision making. We suggest best practices to implement GA in routine practice and clinical trials. The most widely used tool is simplified GA (sGA) which categorizes patients into fit, unfit and frail groups. Patients who are fit benefit from full dose/curative approach, whereas consideration should be made to reduce the intensity of chemotherapy for unfit patients. Frail patients with DLBCL are a major unmet need without any satisfactory treatment options. Ongoing investigations combining novel therapies into chemotherapy-free regimens are underway with promising early results. In the relapsed/refractory (R/R) setting, anti-CD19 CAR-T cell therapy (CART) is now the standard of care for primary refractory disease or relapse within 12 months of completing therapy. Autologous stem cell transplant is still a consideration for fit OA with relapse >12 months after completing therapy. The recent approval of bispecific antibodies is a welcome advance that will greatly benefit OA not eligible for CART. Other regimens available for patients ineligible for CART or for those who experience progression post-CART include polatuzumab-rituximab±bendamustine, tafasitamab-lenalidomide, loncastuximab or chemotherapy-based approaches such as rituximab-gemcitabine-oxaliplatin. We discuss the changing paradigm in R/R DLBCL and spotlight emerging data from recent congresses that can improve outcomes in this vulnerable population.

2024-10-22·Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Article

作者: Houot, Roch ; Abraham, Julie ; Lemonnier, François ; Campidelli, Arnaud ; Tessoulin, Benoit ; Guidez, Stéphanie ; Dupont, Vivien ; Bouabdallah, Krimo ; Jardin, Fabrice ; Tounes, Ledraa ; Hermine, Olivier ; Oberic, Lucie ; Chauchet, Adrien ; Joris, Magalie ; Castilla-Llorente, Cristina ; Brisou, Gabriel ; Marquet, Alexandra ; Decroocq, Justine ; Casasnovas, Olivier ; Fornecker, Luc-Matthieu ; Bailly, Sébastien ; Camus, Vincent ; Herbaux, Charles ; Paillassa, Jérome ; Morschhauser, Franck ; Choquet, Sylvain ; Krzisch, Daphné ; Drieu La Rochelle, Laurianne ; Le Gouill, Steven ; Damaj, Gandhi Laurent ; Carras, Sylvain ; Sesques, Pierre

Abstract:

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, “TL-pre-CAR-T” set) or directly after (n = 52, “TL-post-CAR-T” set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell therapy (mPFS2: 5.6 vs 2 months, P = .0138; mOS2: not reached vs 3.8 months, P = .0034). The bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs 24.9% and 11.6% vs 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 vs 2.4 months, P = .91; mOS2: 3.3 vs 5.5 months, P = .06). In an exploratory analysis of the TL-pre-CAR-T set, the median TAFA-LEN treatment duration before CAR-T was 3.7 months with no patient becoming CD19 negative. The bORR, bCRR, 6- month PFS, and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1%, and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatment improved outcomes for patients relapsing after CAR T-cell therapy.

277

项与坦昔妥单抗相关的新闻（医药）

2024-12-09

·ioncology

ASH圆桌派丨天肿淋巴瘤团队精研细解，共话淋巴瘤领域研究成果与临床实践前沿

编者按 2024年12月7日至10日，第66届美国血液学会（ASH）年会在美国圣迭戈隆重召开，全球血液学专家学者齐聚一堂，共同对血液领域最新研究进展进行深入探讨与交流。在本届会议上，天津医科大学肿瘤医院淋巴瘤团队携6项研究亮相。《血液时讯》特别开辟"ASH圆桌派"精品栏目，邀请团队领头人张会来教授在国内演播厅同步连线其现场参会团队，请各位与会者第一时间进行了研究的深入介绍和参会感悟，国内外视角深刻碰撞。现整理成文，以飨读者，期待为临床实践提供更好的指导与启示。张会来教授此刻来自世界各地的血液学领域的专家学者们正济济一堂，共同分享并深入探讨着血液学研究的最新进展与临床实践成果。很荣幸的是，我们天津医科大学肿瘤医院淋巴瘤团队，今年共有6项研究成果成功入选，包括1项口头报告及5项壁报展示。下面我们将连线各项研究的研究人员，他们此刻正在美国ASH会场，将向大家详细汇报这些研究成果，供各位同仁评述。首先，能否先跟观众先介绍一下ASH会场的基本情况？赵培起教授各位专家、各位同道，大家好。此刻，我们天津医科大学肿瘤医院淋巴瘤团队正身处2024年ASH年会的会场之中。ASH大会历来是我们血液肿瘤领域重点关注的重要学术盛会。今年的大会更是盛况空前，全球范围内超过3万名血液肿瘤领域的专家学者齐聚一堂，同时，大会精心设置了超100场专题会议，旨在深入探讨该领域的最新进展与未来趋势。会议首日，我们见证了众多关于双抗治疗、细胞治疗以及多种新型药物研究的最新成果发布。这些前沿研究为我们提供了宝贵的启示与洞见，让我们对血液肿瘤的治疗策略有了更深入的理解。同时，我们也借此机会与来自全国各地的专家学者进行了深入而富有成效的交流，共同探讨了血液肿瘤领域的热点问题与挑战。我们天肿淋巴瘤团队，在张会来主任的带领下，精心准备了oral演讲及poster展示，旨在借此机会与各位同仁分享我们在淋巴瘤科研领域所取得的一些重要且富有价值的研究成果。在此，我们衷心感谢ASH大会为我们提供的这一交流平台，让我们能够共同学习、共同进步。位。张会来教授可以看到现场非常热烈的学术氛围，我们在国内也深受感染。那么接下来请各位依次介绍一下各自研究的情况。宋拯教授在本年度的ASH会议上，我代表我们中心报告了一项关于泽布替尼联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤（R/R DLBCL）患者的全国多中心临床研究，即BGB-3111-110研究。这项研究由张会来教授牵头，是一项开放标签、剂量递增和扩展的I期临床研究。研究中共纳入了66例患者，其中绝大部分患者为III/IV期，超过40%为原发难治性，同时有50%以上具有高危因素。在剂量爬坡阶段，来那度胺15、20、25mg三个剂量组均未发生剂量限制性毒性，因此在剂量扩展阶段，患者采用来那度胺25mg一天一次联合泽布替尼 160mg一天两次的口服治疗。从总体安全性来看，74%的患者发生≥3级治疗相关不良事件（TEAEs），最常见的是血液性毒性，通常可以通过支持治疗或暂时中断治疗来缓解或恢复。在疗效方面，整体人群的客观缓解率（ORR）达到了50%，其中完全缓解（CR）率达到了35%。在剂量扩展阶段，即来那度胺25毫克每日一次、泽布替尼160毫克每日两次，我们发现ORR进一步提高至58%，完全缓解率提高到42%。本研究取得的高缓解率对于复发/难治性弥漫性大B细胞淋巴瘤患者来说是非常可观的，与目前国际上使用的靶向治疗或靶向联合化疗的方案相比，如维泊妥珠单抗联合BR方案、来那度胺联合Tafasitamab方案，或是最新的双抗治疗方案，其CR率相当。但在我们研究中，泽布替尼联合来那度胺方案在安全性事件发生率方面相对较低。因此，这项研究提示我们，对于复发/难治的弥漫性大B细胞淋巴瘤患者，泽布替尼联合来那度胺的治疗可能达到较高的缓解率，同时缓解的持续时间也比较长，为患者提供了一种便捷且容易接受的治疗方式。高雯博士我本次主要是来介绍并展示一项聚焦于贝林妥欧单抗在真实世界中神经毒性的相关问题的研究。贝林妥欧单抗作为一种抗CD19和抗CD3的双特异性抗体，在近几年血液系统疾病的治疗中展现出了广阔的前景，成为一种有潜力的抗肿瘤药物。然而，其不良事件和副作用也越来越受到大家的关注，尤其是细胞因子释放综合征（CRS）和神经系统相关毒性引起了临床医生的广泛重视。但遗憾的是，目前相关的研究仍然较少。本研究旨在揭示这些关键领域的新结论。我们这项研究主要通过分析美国食品药品监督管理局（FDA）不良事件报告系统（FAERS）数据库中的相关数据来进行，检索了2014年10月1日至2023年9月30日这近十年的数据，并采用了ROR、BCPNN和MGPS等多种算法进行了深入的数据分析。最终，共有5962例患者被纳入统计分析中。通过以上的算法分析，我们发现年轻患者中出现致死性神经毒性的发生率更高。同时，如果患者合并使用其他药物，如泌尿生殖系统或肌肉骨骼系统的药物，也可能增加致死性神经毒性的风险。这提示我们，在临床应用中，对于那些比较年轻的患者，或者是合并使用其他系统药物的患者，需要更加密切地进行神经系统相关毒性的监测，以提高毒性的检出率，从而确保患者的治疗安全性。以上就是本次研究的主要结果，感谢大家的关注。逯亚晓博士在ASH现场，我们深切感受到了浓厚的学术氛围。接下来，我将为大家介绍我们中心的一项研究成果：关于PIM1基因突变促进ANXA2基因膜定位，进而增强弥漫大B细胞淋巴瘤（DLBCL）发病分子机制的研究。众所周知，弥漫大B细胞淋巴瘤具有高度的异质性，其中肿瘤细胞的生物学特性在临床反应和预后方面扮演着至关重要的角色。此前，我们中心已发现PIM1基因突变在弥漫大B细胞淋巴瘤中的频率颇高，约占28.4%。通过多中心的外部数据研究，我们进一步发现PIM1突变患者的预后更差，是OS的一个独立不良预后因素。那么，PIM1基因突变为何会导致预后更差？其关键突变位点又有哪些？为了解答这些问题，我们设计了这项研究。通过更大规模的患者队列研究，我们发现PIM1突变位点主要包括P81S、E135K、S97N和L184F，其中L184F突变的患者预后更差。接着，我们进行了体外实验，发现PIM1突变后，肿瘤细胞的增殖能力显著增强。体内动物实验也显示，携带PIM1突变的小鼠肿瘤体积更大。那么，PIM1突变导致肿瘤侵袭性更强的机制又是什么呢？为了揭示这一机制，我们进行了转录组测序。结果显示，PIM1突变后可以激活PI3K/AKT信号通路。进一步地，为了明晰这一激活机制的具体过程，我们实施了定性的蛋白质组学研究，发现PIM1突变后可以与ANXA2基因发生相互作用，促进其从细胞质定位到细胞膜上，从而增加其活性。此外，活化的ANXA2还可以与TLR4结合，进而激活了下游的PI3K/AKT/mTOR信号通路。在临床应用方面，我们利用高通量药物筛选平台，发现了多种PI3K抑制剂对PIM1突变的患者具有较高的敏感性。当PIM1抑制剂与PI3K抑制剂联合应用时，展现出了协同增效的作用。因此，对于PIM1突变的患者，应用PIM1抑制剂以及PI3K抑制剂可能是一种更有效的治疗策略。以上便是我的研究介绍。赵培起教授本次我所分享的研究，是基于中国多中心真实世界数据的深度剖析，聚焦于Pola-R-CHP治疗方案的应用情况。我们筛选并纳入了131例接受Pola-R-CHP治疗的患者数据以开展此项研究。前期的POLARIX研究已明确表明，相较于传统的R-CHOP方案，Pola-R-CHP能使患者的两年PFS提升6.5%，三年PFS则进一步提升至7.7%。而在今年的ASH年会上，我们更是见证了其五年PFS数据的揭晓，显示出了5.1%的显著提升。然而，值得注意的是，POLARIX研究所纳入的患者群体相对较为单一，合并症较少且整体体质状况良好。与之相比，真实世界中的数据则显得更为复杂和稀缺。鉴于此，我们广泛收集了全国多个医学中心的数据，对131例患者在中位随访时间达12个月的期间内的治疗情况进行了评估与分析。研究结果显示，Pola-R-CHP组的一年PFS达到了90.1%，相比之下，R-CHOP组则为84.3%。尽管这一差异尚未达到统计学上的显著性水平，但患者的生存曲线已呈现出明显的分离趋势，预示着Pola-R-CHP可能具有潜在的临床优势。进一步地，我们进行了深入的亚组分析。结果显示，在某些高危亚组患者中，如Ann Arbor分期为III/IV期、非生发中心B细胞（Non-GCB）以及多个结外受累的患者，Pola-R-CHP组的一年PFS表现均优于R-CHOP组。目前，两组患者的OS尚未观察到显著差异，且安全性表现也相当。此外，我们还对96例患者进行了基因检测。结果显示，MCD亚型占比25%，EZB亚型占比13%，而约30%的患者其风险类型尚无法明确判定。在基因亚型层面，MCD亚组通常预后不佳，而EZB亚组则展现出相对较好的预后，其ORR和CRR均接近100%。同时，我们还发现高危基因突变的患者比例相对较高。具体而言，PIM1基因突变患者占比达到48%，TP53突变患者占比则高达36%。然而，值得注意的是，即便是在TP53突变的患者中，Pola-R-CHP治疗的ORR也达到了82%，CRR为70%；而对于PIM1基因突变患者，其CRR为76%，ORR则高达88%。总之，从整体来看，包括TP53和PIM1在内的基因突变仍然是患者预后不良的重要因素。值得注意的是，在整体人群中，仍有8%的患者在接受了Pola-R-CHP治疗后，疾病仍出现了进展。这一发现提示我们，在治疗前可能需要对患者进行更为精确的评估。对于部分短期内疗效不佳的患者，我们应及时调整治疗方案，如考虑联合双特异性抗体、CAR-T疗法，或者通过多学科会诊来制定更为个体化的治疗方案。此外，鼓励患者参与一些新的临床研究，也是改善这些难治性患者预后的有效途径。以上便是我的分享内容，感谢各位的聆听。张会来教授非常感谢我们团队4位成员的精彩介绍与个人分享。这些研究是我们团队在淋巴瘤领域所做的些许探索，期待这些成果在推动全球淋巴瘤领域的发展进程方面能够略尽绵薄之力。天津医科大学肿瘤医院淋巴瘤内科围绕滤泡性淋巴瘤、套细胞淋巴瘤、结外淋巴瘤及免疫逃逸等4个主要研究方向，积极推进淋巴瘤精准诊疗、新药与新技术的临床研究，并通过拓展与国内外优秀团队的合作，力争实现淋巴瘤患者的精细化、精准化和全程化管理。同时，以临床研究为抓手，加速研究成果的临床转化，以期实现临床研究的长足发展，从而惠及更多淋巴瘤患者，为健康中国战略的实施添砖加瓦。最后，再次谢谢大家的收看。会场花絮张会来教授天津医科大学肿瘤医院（上下滑动查看更多）肿瘤学博士，主任医师，博士研究生导师现任天津医科大学肿瘤医院淋巴瘤内科科主任主要研究方向：恶性淋巴瘤的分子诊断和个体化治疗国家癌症中心淋巴瘤质控专家委员会委员中国抗癌协会第九届理事会理事中国抗癌协会淋巴瘤专业委员会副主任委员中国临床肿瘤学会（CSCO）淋巴瘤专家委员会常委中华医学会肿瘤分会淋巴瘤学组委员天津市抗癌协会肿瘤临床化疗专委会主任委员天津市整合医学会淋巴瘤专业委员会主任委员天津市血液病质控中心副主任委员天津市医师协会血液医师分会副会长入选天津市第二批卫生健康行业高层次人才（津门医学英才）培养计划、天津医科大学“临床人才培养123攀登计划” 第一层次人选培养计划，2023年天津医科大学优秀研究生导师团队。获中华医学科技奖三等奖1项、中国抗癌协会科普奖1项、天津市科技进步二等奖1项及三等奖3项，主持及参与多项国家自然科学基金课题及省部级科研项目。目前担任《肿瘤药学》副主编、《中华血液学杂志》、《白血病∙淋巴瘤》、《中国肿瘤临床》、《Hematological Oncology》、《Blood Research》、《Discover Oncology》等国内外期刊杂志编委, 以第一或通讯作者在Blood、Cancer Research、J Exp Med、JITC、Leukemia、CTM、AJH 、BJH、 Blood Adv 、Int J Cancer 等国际专业杂志以及中华系列杂志、国家级核心期刊发表论著九十余篇。荣获第四届 “国之名医·优秀风范”奖。赵培起天津医科大学肿瘤医院（上下滑动查看更多）医学博士副主任医师天津医科大学肿瘤医院淋巴瘤内科主要从事淋巴瘤的内科诊治及基础、临床研究。主持国家自然科学基金一项，参与多项国家及省部级课题，发表SCI文章二十余篇。作为编委及执笔专家参与制定CSCO及CACA淋巴瘤诊疗指南。中国医促会肿瘤内科学分会第二届委员会委员中国老年保健协会淋巴瘤专业委员会委员北京癌症防治学会淋巴瘤免疫治疗专业委员会常务委员天津市抗癌协会淋巴瘤专业委员会委员天津市抗癌协会淋巴瘤青委会副主任委员天津市抗癌协会肿瘤临床化疗专业委员会委员天津市抗癌协会肿瘤药物临床研究专业委员会委员宋拯天津医科大学肿瘤医院（上下滑动查看更多）天津医科大学肿瘤医院淋巴瘤科副主任医师国家淋巴瘤质控专家委员会青委会委员中国抗癌协会淋巴瘤整合康复专委会委员中国老年保健协会肿瘤免疫治疗专委会委员中国老年保健协会淋巴瘤专委会委员天津市抗癌协会淋巴瘤专委会委员兼秘书天津市抗癌协会肿瘤临床化疗专委会委员兼秘书天津市整合医学学会转化医学专委会常委天津市整合医学学会淋巴瘤专委会委员天津市整合医学学会病理专委会委员美国莫非特癌症中心访问学者高雯天津医科大学肿瘤医院（上下滑动查看更多）天津医科大学博士在读主治医师天津医科大学肿瘤医院淋巴瘤内科济南市第四人民医院心内科主要从事心肌重构、心力衰竭、抗肿瘤药物毒性等基础及临床研究。主持山东省卫健委课题两项，济南市卫健委课题两项，参与多项国家及省部级课题，发表SCI文章十余篇。济南市预防医学会心血管病防治专业委员会副主任委员济南医学会心脏急重症专业委员会委员兼秘书济南中医药学会心律失常专业委员会委员兼秘书山东省中医药学会心律失常专业委员会委员山东省康复会心脏康复专业委员会青年委员逯亚晓肿瘤学博士（上下滑动查看更多）现就读于天津医科大学，导师张会来教授主要研究方向：恶性淋巴瘤的基础及临床研究以第一或共同第一作者在CTM、AJH 、Clin Immunol、Cancer Res等国际专业杂志以及国家级核心期刊发表论著6篇。在学期间荣获国家奖学金、天津医科大学优秀研究生荣誉称号。（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

ASH会议临床1期

2024-11-28

·PRNewswire

Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse after conventional chemotherapy regimens. This paradigm shift is characterized by the emergence of innovative therapies like CAR T-cell therapy and bispecific antibodies, which have demonstrated remarkable efficacy in targeting and eradicating lymphoma cells. CAR T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered to recognize and attack cancer cells. This personalized treatment has shown significant promise, especially for individuals who have undergone extensive previous therapies. One notable example is Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy approved for use in patients with relapsed or refractory follicular lymphoma. Clinical trials have highlighted its ability to induce durable remissions, with some patients experiencing long-term remission even after multiple prior therapies. LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the follicular lymphoma pipeline domain. Key Takeaways from the Follicular Lymphoma Pipeline Report DelveInsight's follicular lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for follicular lymphoma treatment. Key follicular lymphoma companies such as Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others are evaluating new follicular lymphoma drugs to improve the treatment landscape. Promising follicular lymphoma pipeline therapies such as Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others are under different phases of follicular lymphoma clinical trials. In August 2024, the company expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with FL who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024 based on the positive Phase III results. In June 2024, a consortium of Eugene Private Equity and Korea Development Bank Private Equity announced that they would acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million). In February 2024, Incyte announced that it had entered into an asset purchase agreement with MorphoSys AG, which gives Incyte exclusive global rights for tafasitamab. Incyte will now recognize revenue and cost for all US commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments. In September 2023, OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate. The ONM-501 first-in-human trial is a multicenter Phase Ia/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid tumors and lymphomas. OncoNano is the sponsor of the clinical trial, and Regeneron will supply cemiplimab. In May 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. Under the terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the Chinese territory. Janssen will make an upfront payment of USD 245 million that will be accounted for in the second quarter as a research and development expense. Additional future payments will be based upon achieving certain development, regulatory, and sales milestones, as well as tiered royalty payments on worldwide net trade sales, excluding Greater China. Request a sample and discover the recent advances in follicular lymphoma treatment drugs @ Follicular Lymphoma Pipeline Report The follicular lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage follicular lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the follicular lymphoma clinical trial landscape. Follicular Lymphoma Overview Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This cancer is characterized by the growth of abnormal lymphoid follicles, which can disrupt normal lymphatic function. While the exact causes of follicular lymphoma are not fully understood, certain factors may increase the risk, including age (most commonly affecting adults over 60), a family history of lymphoma, and potential environmental factors such as exposure to pesticides or chemicals. Symptoms of follicular lymphoma can vary widely but may include painless swelling of lymph nodes in the neck, armpit, or groin, unexplained weight loss, night sweats, fatigue, and fever. Some patients may remain asymptomatic for extended periods, as this type of lymphoma can progress slowly. Diagnosis typically involves a combination of physical examinations, blood tests, imaging studies (like CT scans), and a biopsy of affected lymph nodes. The biopsy helps determine the subtype and stage of the lymphoma, which is crucial for planning treatment. Treatment for follicular lymphoma depends on the stage of the disease and the patient's overall health. Options may include watchful waiting for asymptomatic cases, chemotherapy, immunotherapy (such as monoclonal antibodies), and targeted therapies. In some cases, stem cell transplants may be considered for patients with more aggressive forms or those who do not respond to initial treatments. Given the indolent nature of follicular lymphoma, ongoing management, and regular monitoring are vital for achieving the best possible outcomes. Find out more about follicular lymphoma treatment drugs @ Drugs for Follicular Lymphoma Treatment A snapshot of the Follicular Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging follicular lymphoma pipeline therapies @ Follicular Lymphoma Clinical Trials Follicular Lymphoma Therapeutics Assessment The follicular lymphoma pipeline report proffers an integral view of the follicular lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Follicular Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitors, Phosphatidylinositol 3 kinase gamma inhibitors, Emt protein-tyrosine kinase inhibitors, Interleukin 15 receptor agonists, Histone deacetylase inhibitors, Rad51 recombinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Enhancer of zeste homolog 2 protein inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death 1 receptor antagonists, T lymphocyte stimulants, Alkylating agents, DNA cross-linking agents Key Follicular Lymphoma Companies: Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others. Key Follicular Lymphoma Pipeline Therapies: Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others. Dive deep into rich insights for new drugs for follicular lymphoma treatment, visit @ Follicular Lymphoma Drugs Table of Contents For further information on the follicular lymphoma pipeline therapeutics, reach out @ Follicular Lymphoma Treatment Drugs Related Reports Follicular Lymphoma Market Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies including Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

免疫疗法引进/卖出临床3期疫苗细胞疗法

2024-11-26

·ioncology

2024 ASH重磅丨六项LBA摘要公布，一文了解血液学最前沿

编者按第66届美国血液学会（ASH）年会将于2024年12月7～10日在美国圣迭戈（San Diego）盛大召开。作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一，每年吸引着成千上万名来自世界各地的专家学者，分享最前沿的血液学进展和突破性临床数据。当地时间11月25日，大会官网公布了本次入选的最新重磅摘要（Late-Breaking Abstracts，LBA）共6项，将由研究者于当地时间2024年12月10日上午7:30至9:00，在会议现场Hall B (San Diego Convention Center)进行报告。本刊第一时间整理这6项LBA的核心要点，供大家提前阅览。 01 LBA-1 标题：Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND) 中文标题：坦昔妥单抗联合来那度胺和利妥昔单抗治疗复发或难治性滤泡性淋巴瘤：III期研究（inMIND）结果汇报人：Laurie H. Sehn（BC癌症中心淋巴瘤中心，加拿大）研究结论在来那度胺和利妥昔单抗的基础上加用坦昔妥单抗，显著且有临床意义地改善了无进展生存期（PFS），使复发/难治性滤泡性淋巴瘤（R/R FL）患者的疾病进展、复发或死亡风险降低了57%。尽管总生存期（OS）数据尚不成熟，但观察到了一种有利于塔坦昔妥单抗的趋势。其安全性特征可控，且与预期毒性一致。本研究首次验证了将两种单克隆抗体（抗CD19与抗CD20）联合用于淋巴瘤治疗的有效性。坦昔妥单抗+来那度胺+利妥昔单抗既可在社区环境中使用，也可在学术环境中使用，是R/R FL患者潜在的新标准治疗选择。 02 LBA-2 标题：Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis 中文标题：识别具有增强活性的肝样促红细胞生成素作为遗传性和获得性红细胞增多症的新原因汇报人：Betty Gardie[巴黎高等研究实践学院（EPHE），法国] 研究结论本研究报告了一种名为肝样促红细胞生成素增多症（HEP）的新型继发性红细胞增多症，其特征是产生具有非典型糖基化模式和活性增强的肝样促红细胞生成素（EPO）。这种新型EPO在所有遗传性EPO突变型红细胞增多症患者、与肝病相关的红细胞增多症病例以及新生儿中均有观察到。有趣的是，新生儿体内从更活跃的肝型EPO向肾型EPO的转变，可能解释了生命最初几周内血红蛋白水平显著下降的典型现象。因此，在进行特发性和遗传性红细胞增多症的诊断时，将定量和定性EPO筛查作为生物学检查的一部分是至关重要的。 03 LBA-3 标题：Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence 中文标题：比较减剂量与全剂量直接口服抗凝药延长治疗高风险复发静脉血栓栓塞症 Francis Couturaud（布雷斯特大学、FCRIN INNOVTE网络，法国）研究结论在需要延长抗凝治疗的静脉血栓栓塞症患者中，尚无法证明使用减剂量与全剂量直接抗凝药物在预防静脉血栓栓塞症复发方面的非劣效性。在减剂量组，临床相关出血以及静脉血栓栓塞症复发或临床相关出血的复合终点发生率均低于全剂量组，且这一优势并未因死亡或动脉血栓栓塞事件风险增加而抵消。 04 LBA-4 标题：Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) 中文标题：富含安第斯特征的NFKB1单倍型可降低真性红细胞增多症（PV）和原发性血小板增多症（ET）患者的炎症水平，并提高对罗培干扰素α-2b的应答率汇报人：Jihyun Song（亨斯迈癌症研究所，美国）研究结论本研究显示，与NFKB1野生型等位基因相比，富含艾马拉族特征的NFKB1 rs230511单倍型可降低真性红细胞增多症（PV）和原发性血小板增多症（ET）患者的炎症、促血栓形成及缺氧诱导因子（HIF）活性。此外，NFKB1 rs230511单倍型还能调节PV和ET患者对罗培干扰素的应答。携带NFKB1 rs230511 T等位基因的患者，其炎症和HIF靶向基因的表达降低，这可能潜在地减少PV和ET患者的炎症和血栓形成风险。携带C/T基因型的患者更有可能实现完全血液学缓解（CHR），这表明这种NFKB1单倍型可能影响罗培干扰素的治疗效果，并可作为评估PV和ET患者治疗应答的潜在生物标志物。这些新的见解对我们理解炎症和促血栓形成过程具有重要意义，并可能为PV和ET的新型疗法提供线索。 05 LBA-5 标题：Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities 中文标题：Drepagreffe试验中接受异体干细胞移植与标准治疗的镰状细胞贫血症伴异常脑血流速度病史患儿的10年脑血管病变情况及认知功能结局比较汇报人：Françoise Bernaudin（巴黎东部大学，法国）研究结论这项首个前瞻性比较试验表明，异体干细胞移植（alloSCT）与标准治疗（SoC）之间的差异在10年后发生了显著变化，其中异体干细胞移植在无症状性脑梗死（SCI)方面提供了更好的一级预防效果，同时改善了患者的社会生活质量、工作记忆和处理速度。 06 LBA-6 标题：Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial 中文标题：自体造血干细胞移植（auto-HCT）对首次完全缓解（CR）且无法检测到微小残留病（uMRD）的套细胞淋巴瘤（MCL）患者（pts）无益处：ECOG-ACRIN EA4151 III期随机试验的初步报告汇报人：Timothy S. Fenske（威斯康星医学院，美国）研究结论本次中期分析显示，在高效诱导和维持治疗方案时代，首次完全缓解（CR）且无法检测到微小残留病（uMRD）的套细胞淋巴瘤（MCL）患者并未从巩固性自体造血干细胞移植（auto-HCT）中获益。而诱导治疗后MRD仍为阳性的患者可能从auto-HCT中获益。更长时间的随访对于证实这些发现至关重要。（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床结果

100 项与坦昔妥单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	DB15044

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
复发性弥漫性大B细胞淋巴瘤	加拿大	Incyte Corp.	2021-08-19
难治性弥漫性大 B 细胞淋巴瘤	加拿大	Incyte Corp.	2021-08-19
弥漫性大B细胞淋巴瘤	美国	MorphoSys AG	2020-07-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
滤泡性淋巴瘤	临床3期	美国	MorphoSys AG	2022-01-30
边缘区B细胞淋巴瘤	临床3期	美国	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	日本	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	澳大利亚	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	奥地利	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	比利时	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	加拿大	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	捷克	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	丹麦	Incyte Corp.	2021-04-15
边缘区B细胞淋巴瘤	临床3期	芬兰	Incyte Corp.	2021-04-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	复发性弥漫性大B细胞淋巴瘤	-	Tafasitamab + Lenalidomide	糧鏇構鏇夢範壓積鏇獵(範鏇觸窪艱壓糧齋糧襯) = 艱顧簾鏇壓願鏇積網蓋糧鏇構繭願壓繭憲夢襯 (選蓋餘鏇積繭鹹膚鹹鹹, 1 ~ 3+)	-	2024-12-08
				Tafasitamab (Real-World Setting)	糧鏇構鏇夢範壓積鏇獵(範鏇觸窪艱壓糧齋糧襯) = 網憲壓觸窪構繭糧衊衊糧鏇構繭願壓繭憲夢襯 (選蓋餘鏇積繭鹹膚鹹鹹, 1 ~ 3+)
NCT04134936 (FIRST-MIND, CTgov)	临床1期	弥漫性大B细胞淋巴瘤	66	Tafasitamab (Arm A)	鹹膚範鏇餘淵築構鏇齋(襯窪網築衊製顧製壓壓) = 廠願壓膚蓋鹽膚範膚鹹窪選選夢顧廠築構鏇鏇 (鑰鑰遞膚網選鏇遞鏇窪, 積繭夢襯壓鹽製觸觸壓 ~ 壓憲淵襯遞壓壓獵選構) 更多	-	2024-10-16
				lenalidomide+Tafasitamab (Arm B)	鹹膚範鏇餘淵築構鏇齋(襯窪網築衊製顧製壓壓) = 醖築鑰鏇夢齋窪鬱淵顧窪選選夢顧廠築構鏇鏇 (鑰鑰遞膚網選鏇遞鏇窪, 鹽鏇膚鹹餘廠艱廠蓋廠 ~ 憲廠憲積艱鏇糧夢襯糧) 更多
SOHO2024	N/A	复发性弥漫性大B细胞淋巴瘤	-	Tafasitamab (Primary Refractory DLBCL)	遞範醖簾夢範廠壓築積(衊願窪醖餘積網鹹構構) = 壓夢築築鬱顧夢鏇襯膚餘醖廠鏇糧廠膚齋範鏇 (艱願顧網遞鬱鹽鹹鑰廠, 47.8 ~ 75.6)	-	2024-09-04
				Tafasitamab (Nonprimary Refractory DLBCL)	遞範醖簾夢範廠壓築積(衊願窪醖餘積網鹹構構) = 壓膚簾繭襯餘糧簾窪構餘醖廠鏇糧廠膚齋範鏇 (艱願顧網遞鬱鹽鹹鑰廠, 65.6 ~ 80.6)
NCT05552937 (ICP-CL-00901, EHA2024) 人工标引	临床2期	弥漫性大B细胞淋巴瘤	52	Tafasitamab cLenalidomide Lenalidomide	(網醖窪夢窪淵鑰積艱糧) = 築繭鑰壓觸選製構壓夢艱製選選淵構鹹構廠繭 (願壓膚蓋鏇遞願齋願艱, 52.9 ~ 79.7) 更多	积极	2024-05-14
NCT05429268 (firmMIND, EHA2024)	临床2期	弥漫性大B细胞淋巴瘤 CD19+	6	Tafasitamab	觸觸遞餘淵餘範糧鑰醖(蓋醖餘鏇窪鏇簾鹹醖簾) = 鬱膚餘繭淵蓋鹽觸膚蓋繭鹽範網積壓構簾憲鑰 (憲築願遞繭壓遞廠繭顧 )	积极	2024-05-14
				Placebo	觸觸遞餘淵餘範糧鑰醖(蓋醖餘鏇窪鏇簾鹹醖簾) = 衊遞憲獵醖夢餘鏇衊淵繭鹽範網積壓構簾憲鑰 (憲築願遞繭壓遞廠繭顧 )
L-MIND (EHA2024)	临床2期	弥漫性大B细胞淋巴瘤	-	Tafasitamab-lenalidomide (T/L)	顧憲繭範範淵範獵襯製(襯製窪窪選窪憲積膚獵) = 網衊淵選糧鬱觸網鏇襯選衊齋餘壓蓋鹽繭淵鏇 (遞鬱鬱膚繭顧選選鏇築 ) 更多	积极	2024-05-14
L-MIND trial (EHA2024)	临床2期	弥漫性大B细胞淋巴瘤 CD19	181	Tafasitamab + Lenalidomide	鹹範範繭遞糧鑰築衊願(蓋獵齋繭廠鑰廠齋範鑰) = 蓋憲齋鹽膚艱糧廠夢鬱鹽繭壓鑰衊鹽餘製淵糧 (選淵繭觸願襯蓋獵蓋鏇, 13 ~ 24) 更多	积极	2024-05-14
EarlyMIND (EHA2024)	N/A	大B细胞淋巴瘤	214	Tafasitamab and lenalidomide combination therapy (TL)	鬱糧遞網範憲餘積鬱齋(窪願齋鹽觸蓋齋鏇壓衊) = 願鹽憲繭繭觸築襯窪窪衊構蓋膚窪窪淵衊壓淵 (鏇醖淵網窪遞醖衊憲窪, 39.4 ~ 54.2) 更多	积极	2024-05-14
				Tafasitamab-Lenalidomide (Cohort A)	鬱糧遞網範憲餘積鬱齋(窪願齋鹽觸蓋齋鏇壓衊) = 蓋鏇夢願艱觸鹹鏇醖積衊構蓋膚窪窪淵衊壓淵 (鏇醖淵網窪遞醖衊憲窪, 40.6 ~ 60.4) 更多
Smart Stop (ASH2023)	N/A	弥漫性大B细胞淋巴瘤	30	Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib	淵鬱簾鏇積鏇築製範廠(壓獵糧鏇夢廠繭繭選鏇) = 鏇醖艱齋獵淵膚艱艱範窪鏇壓艱簾製淵製蓋範 (遞夢衊夢繭鹽製窪鑰鏇 ) 更多	-	2023-12-11
				Lenalidomide, Tafasitamab, Rituximab, Acalabrutinib, and CHOP therapy	淵鬱簾鏇積鏇築製範廠(壓獵糧鏇夢廠繭繭選鏇) = 餘齋積餘襯淵簾襯糧獵窪鏇壓艱簾製淵製蓋範 (遞夢衊夢繭鹽製窪鑰鏇 ) 更多
ASH2023 人工标引	N/A	弥漫性大B细胞淋巴瘤三线 \| 二线	-	Tafasitamab	遞獵廠築齋簾築築鏇壓(願襯網範壓製築製糧積) = 醖製壓壓醖簾夢築選網蓋憲獵鏇廠簾積鑰衊壓 (觸鹹膚觸艱淵獵壓觸鬱, 69.1 ~ 82.1) 更多	积极	2023-12-09
				Tafasitamab (Received in 2L)	遞獵廠築齋簾築築鏇壓(願襯網範壓製築製糧積) = 廠觸顧簾蓋壓繭鹹獵餘蓋憲獵鏇廠簾積鑰衊壓 (觸鹹膚觸艱淵獵壓觸鬱, 72.6 ~ 86.8) 更多